HC Wainwright Has Weak Estimate for Septerna FY2026 Earnings

Septerna, Inc. (NASDAQ:SEPN) – Equities research analysts at HC Wainwright reduced their FY2026 earnings per share estimates for shares of Septerna in a report issued on Tuesday, November 10th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings of ($1.48) per share for the year, down from their prior estimate of ($1.15). HC Wainwright currently has a “Buy” rating and a $60.00 target price on the stock. The consensus estimate for Septerna’s current full-year earnings is ($1.41) per share. HC Wainwright also issued estimates for Septerna’s Q4 2026 earnings at ($0.41) EPS, Q1 2027 earnings at ($0.36) EPS, Q3 2027 earnings at ($0.34) EPS, Q4 2027 earnings at ($0.37) EPS and FY2027 earnings at ($1.34) EPS.

Several other research analysts have also commented on SEPN. Raymond James Financial reaffirmed a “strong-buy” rating and set a $49.00 price objective on shares of Septerna in a research note on Tuesday, August 11th. JPMorgan Chase & Co. increased their target price on shares of Septerna from $38.00 to $48.00 and gave the company an “overweight” rating in a research note on Wednesday, August 19th. JonesTrading raised their target price on shares of Septerna from $43.00 to $62.00 and gave the stock a “buy” rating in a report on Thursday, August 13th. Wells Fargo & Company lifted their price target on shares of Septerna from $50.00 to $61.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 4th. Finally, Guggenheim upped their price target on shares of Septerna from $51.00 to $65.00 and gave the company a “buy” rating in a report on Friday, November 6th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $56.44.

Septerna Stock Down 7.2%

Shares of SEPN opened at $48.56 on Thursday. The company has a market cap of $2.27 billion, a PE ratio of -37.64 and a beta of 2.20. The business has a fifty day moving average of $40.26 and a 200 day moving average of $32.95. Septerna has a 52-week low of $18.64 and a 52-week high of $53.34.

Septerna (NASDAQ:SEPN) last released its earnings results on Monday, November 9th. The company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.15). Septerna had a negative net margin of 61.29% and a negative return on equity of 14.98%. The company had revenue of $18.88 million for the quarter, compared to the consensus estimate of $20.78 million.

Institutional Trading of Septerna

A number of hedge funds and other institutional investors have recently bought and sold shares of SEPN. Voya Investment Management LLC bought a new position in shares of Septerna in the third quarter worth about $565,000. Russell Investments Group Ltd. lifted its holdings in Septerna by 8.6% during the 3rd quarter. Russell Investments Group Ltd. now owns 43,683 shares of the company’s stock valued at $1,709,000 after buying an additional 3,474 shares in the last quarter. Covestor Ltd lifted its holdings in Septerna by 19.0% during the 3rd quarter. Covestor Ltd now owns 2,526 shares of the company’s stock valued at $98,000 after buying an additional 403 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Septerna in the 3rd quarter valued at about $93,000. Finally, Profund Advisors LLC purchased a new stake in Septerna in the 3rd quarter valued at about $1,497,000.

Insider Buying and Selling

In related news, COO Elizabeth Bhatt sold 4,000 shares of the firm’s stock in a transaction that occurred on Thursday, October 15th. The stock was sold at an average price of $37.41, for a total transaction of $149,640.00. Following the completion of the sale, the chief operating officer directly owned 174,209 shares of the company’s stock, valued at approximately $6,517,158.69. This trade represents a 2.24% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Daniel Long sold 3,333 shares of the business’s stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $37.83, for a total value of $126,087.39. Following the transaction, the senior vice president owned 96,412 shares of the company’s stock, valued at approximately $3,647,265.96. The trade was a 3.34% decrease in their position. The SEC filing for this sale provides additional information. 5.80% of the stock is currently owned by company insiders.

Septerna News Summary

Investors following SEPN have been watching these news items:

• Positive Sentiment: HC Wainwright maintained its Buy rating and $60 target. It raised its FY2027 EPS estimate to a loss of $1.34 per share from $1.41, and also improved its Q3 and Q4 2027 estimates.
• Positive Sentiment: A separate report said Septerna reached a new 52-week high following an analyst upgrade, reflecting recent investor interest. Septerna Reaches New 52-Week High Following Analyst Upgrade
• Negative Sentiment: HC Wainwright lowered its FY2026 EPS estimate to a loss of $1.48 from $1.15, and reduced forecasts for Q4 2026 and Q1 2027. These revisions point to larger expected near-term losses, partly offsetting its more optimistic 2027 outlook.

Septerna Company Profile

Septerna is a clinical-stage biotechnology company developing medicines that target G protein-coupled receptors (GPCRs), a large family of proteins involved in many biological processes. The company is based in South San Francisco, California. Its discovery platform is designed to identify drug candidates that act on GPCRs, including targets that have been difficult to address with conventional drug-development approaches. Septerna is advancing candidates for endocrine, metabolic and other disease areas, with an emphasis on small-molecule medicines.